Steady first half

EKF Diagnostics Holdings (LSE:EKF) (AIM: EKF) has reported interim results for the six months to 30 June 2026, showing stable revenue, firmer margins and an order book the board believes supports full-year growth in line with consensus. Revenue was £25.0 million, Gross Profit £13.3 million and adjusted EBITDA £5.9 million, up 2.4%. For a company in the FTSE AIM All Share index with a long record in diagnostics, the result reads as consolidation rather than acceleration.

What EKF does

EKF is a diagnostics Business reporting through two main areas. Its Point-of-Care division sells testing devices designed for use close to the patient rather than in central laboratories. Its Life Sciences division supplies materials to the laboratory and diagnostics markets and, as its 2021 trading history shows, has also undertaken contract manufacturing, including Covid-19 sample collection devices and kits. The company reports in sterling and sells to customers in many international markets.

The interim figures

Beyond headline revenue, LSE:EKF reported a gross Margin improved to 53.0% and profit before tax of £3.4 million. Cash stood at £16.0 million at 30 June 2026. Life Sciences was described as resilient, while Point-of-Care revenues recovered after a weaker patch. The company said it has a solid committed order book for the second half.

Recent trading history

The company has been issuing regular trading comment. A statement on 19 May 2026 said trading for the year was in line with management expectations, and on 12 June 2026 EKF announced that it had bought back and cancelled 50,000 of its own shares, a small but visible sign of Capital allocation. Full-year results for 2025 were published on 24 March 2026. Readers should note that the solid trading of 2021, when Covid-19 sample collection devices lifted half-year revenue to £38.56 million, is old news and no longer the driver of results, with the latest half-year revenue of £25.0 million well below that peak.

Sector and index context

Diagnostics companies face contrasting pressures. Demand for testing is structurally supported by ageing populations and chronic disease monitoring, yet hospital and distributor budgets can be tight and orders can be lumpy from quarter to quarter. Currency can matter for any exporter reporting in sterling. Within the FTSE AIM All Share Index, EKF (LSE:EKF) is one of a limited number of profitable, cash-generative medical technology names, which tends to make it a reference point for the sector.

Key risks

Diagnostics orders can be lumpy, so a timing shift can move a half-year result, and the Point-of-Care recovery described in the interim announcement may not be linear. Foreign exchange swings, input costs and tariffs on cross-border shipments are further variables. Regulatory approvals for new products can be slow and costly. Competitors in diagnostics are often far larger.

What to watch next

The key marker is whether second-half delivery supports the board's expectation of growth in line with consensus. Investors will watch the pace of order conversion, margin progress, any update on the buyback and the timing of the 2026 full-year results, which LSE:EKF has historically published in March, including any Dividend decision and the cash position at year end.